Previous Page Next Page

A number of different technologies are being used to screen for synthetic lethal combinations, including small interfering RNA (siRNA) screens, small molecule screening in haploid human cells, and exploiting CRISPR-Cas9 based knock-out/knock-in strategies.

From these screening studies, new synthetic lethality targets have been identified, including POLQ (Polθ) and RNASEH2B.

POLQ is required for micro-homology mediated end joining (MMEJ), and it is upregulated and acts as a backup double-strand break repair pathway in HRD. In cancer cells lacking HRR, POLQ-inhibition results in synthetic lethality, via a mechanism that is distinct from PARP inhibition [1-3]. To date POLQ deficiency has been shown to be synthetic lethal with several other cellular pathways, including BRCA, ATM, Ku, 53BP1 and FA pathway mutations [3].

Loss of RNASEH2B in metastatic prostate cancer and chronic lymphocytic leukemia increases PARP-trapping DNA lesions, offering another therapeutic target based on synthetic lethality [4].

See the DDR Compounds in Development section for more information.

References

  1. Ceccaldi R, Liu JC, Amunugama R et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature 2015; 518: 258-262.
  2. Mateos-Gomez PA, Gong F, Nair N et al. Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Nature 2015; 518: 254-257.
  3. Gourley C, Balmana J, Ledermann JA et al. Moving from PARP Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol 2019; doi: 10.1200/JCO.1218.02050. [Epub ahead of print].
  4. Zimmermann M, Murina O, Reijns MAM et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 2018; 559: 285-289.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings